Your browser doesn't support javascript.
loading
Performance of [68Ga]Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients.
Afshar-Oromieh, Ali; da Cunha, Marcelo Livorsi; Wagner, Jairo; Haberkorn, Uwe; Debus, Nils; Weber, Wolfgang; Eiber, Matthias; Holland-Letz, Tim; Rauscher, Isabel.
Afiliação
  • Afshar-Oromieh A; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany. ali.afshar@insel.ch.
  • da Cunha ML; Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstr. 18, CH-3010, Bern, Switzerland. ali.afshar@insel.ch.
  • Wagner J; Department of Nuclear Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Haberkorn U; Department of Nuclear Medicine, Hospital Israelita Albert Einstein, São Paulo, Brazil.
  • Debus N; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
  • Weber W; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Centre, Heidelberg, Germany.
  • Eiber M; Department of Nuclear Medicine, Heidelberg University Hospital, Heidelberg, Germany.
  • Holland-Letz T; Department of Nuclear Medicine, Technical University of Munich, Munich, Germany.
  • Rauscher I; Department of Nuclear Medicine, Technical University of Munich, Munich, Germany.
Eur J Nucl Med Mol Imaging ; 48(9): 2925-2934, 2021 08.
Article em En | MEDLINE | ID: mdl-33543325
PURPOSE: To evaluate the performance of [68Ga]Ga-PSMA-11 PET/CT in the diagnosis of recurrent prostate cancer (PC) after prostatectomy in a large multicentre cohort. METHODS: The centres, which contributed to this study, were the departments of nuclear medicine of Heidelberg (Germany), Technical University of Munich (Germany) and Albert Einstein Hospital of São Paulo (Brazil). A total of 2533 patients who were scanned with [68Ga]Ga-PSMA-11 PET/CT at 1 h p.i. due to recurrent PC after prostatectomy were included in this retrospective analysis. Exclusion criteria were as follows: patients with untreated primary tumour, previous chemotherapy or Xofigo®; those previously treated with exclusively external beam radiation therapy or HIFU; those referred for PSMA-therapy; and those treated with ADT (including first- and second-generation ADT) within the last 6 months. Potential influences of different factors such as PSA level, PSA doubling-time (PSADT), PSA velocity (PSAVel), Gleason Score (GSC, including the separate analysis of 7a and 7b), age and amount of injected tracer were evaluated in a multivariable analysis. RESULTS: The rate of pathologic PET/CT-scans was 43% for PSA ≤ 0.2 ng/ml, 58% for PSA > 0.2 to ≤ 0.5, 72% for PSA > 0.5 to ≤ 1.0 and increased to a maximum of 93% for PSA > 10 ng/ml. A pathological PET/CT was significantly (p = 0.001) associated with PSA level and higher GSC. Amount of injected tracer, age, PSADT and PSAVel were not associated with a higher probability of a pathological scan. CONCLUSION: [68Ga]Ga-PSMA-11 PET/CT at 1 h p.i. confirmed its high performance in the largest patient cohort yet analysed. Tumour detection showed a clear association with higher PSA and higher GSC. No association was found between a pathological [68Ga]Ga-PSMA-11 PET/CT and age, amount of injected tracer, PSADT or PSAVel.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans / Male País/Região como assunto: America do sul / Brasil / Europa Idioma: En Revista: Eur J Nucl Med Mol Imaging Assunto da revista: MEDICINA NUCLEAR Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Tomografia por Emissão de Pósitrons combinada à Tomografia Computadorizada Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans / Male País/Região como assunto: America do sul / Brasil / Europa Idioma: En Revista: Eur J Nucl Med Mol Imaging Assunto da revista: MEDICINA NUCLEAR Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Alemanha País de publicação: Alemanha